Medical interventions involve risks and benefits — and an implicit or explicit weighing of benefits against the risks. This can be difficult to do, mostly because both can be highly individual. This is the case with the Astra Zeneca vaccine saga.

Let’s start with the risks, the clearer part of the equation. The AZ vaccine is probably associated with an increase in the rate of specific rate types of blood clots, as concluded by both the EMA in the EU and the MHRA in the UK. These side effects are however extremely rare: 86 with 18 fatal out of about…

Theodor Bălan